QALY

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

Retrieved on: 
Wednesday, January 17, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Diabetes, Patient, Therapy, Quality-adjusted life year, SOC, Society, Digital, Type 2 diabetes, American Diabetes Association, Better, Cognitive behavioral therapy, Advances in Therapy, ICER, A1C, QALY, Life imprisonment, Prevalence, Pharmaceutical industry

The study's authors conclude that, from a healthcare payer perspective, AspyreRx plus standard of care (SoC) was estimated to be both economically and clinically superior to SoC alone over the lifetime horizon.

Key Points: 
  • The study's authors conclude that, from a healthcare payer perspective, AspyreRx plus standard of care (SoC) was estimated to be both economically and clinically superior to SoC alone over the lifetime horizon.
  • This suggests that the use of AspyreRx can empower patients to better manage their diabetes with the potential for lifelong advantages.
  • This latest study modeled the cost-effectiveness of AspyreRx plus SoC versus SoC alone in T2D over a lifetime horizon.
  • "The publication of this data, demonstrating that adding AspyreRx to standard of care has the potential to be more effective and less costly than standard of care alone, exemplifies our vision to make societies healthier and meaningfully reduce healthcare costs.”

New Video: Discriminatory Metrics Have No Place in Healthcare

Retrieved on: 
Tuesday, October 31, 2023
Research, Quality-adjusted life year, Ageing, Notifiable disease, Food, Health, Medicare, Alliance for Aging Research, Human, Communication, QALY, Interview, Bangladesh Technical Education Board, ICER, Evli, Patient, Pharmaceutical industry

WASHINGTON, Oct. 31, 2023 /PRNewswire/ -- The Alliance for Aging Research today released a new educational video warning against discriminatory drug pricing metrics promoted by the Institute for Clinical and Economic Review (ICER).

Key Points: 
  • "There is no place in our healthcare system for outdated metrics that blatantly value some lives over others," said Alliance for Aging Research Public Policy Manager, Adina Lasser.
  • "Metrics like QALY and evLYG are nothing more than mechanisms to discriminate against those who need access to care the most.
  • The Alliance for Aging Research has been a leading voice against the QALY, evLYG, and other discriminatory metrics in drug pricing.
  • To learn more about ICER and how it promotes discriminatory drug pricing through the QALY and evLYG mechanisms, visit IcerFacts.org .

Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Retrieved on: 
Thursday, October 26, 2023
Nexus, Patient, FDA, Academy of Managed Care Pharmacy, Research, Standard of care, Cyclophosphamide, Food, Outcomes research, ClinicoEconomics and Outcomes Research, Treatment, NS, Adrenocorticotropic hormone (medication), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, D20, QALY, Poster, Nephrotic syndrome, Congenital nephrotic syndrome, Adrenocorticotropic hormone, Sarcoidosis, Chlorambucil, Rituximab, Symphony, ICER, SOC, Calcineurin, AMCP, Azathioprine, Diagnosis, Proteinuria, Pharmaceutical industry, Medical imaging, Mallinckrodt

DUBLIN, Oct. 26, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, recently shared findings from Mallinckrodt's latest health economics outcomes research on Acthar® Gel (repository corticotropin injection) for patients with advanced symptomatic sarcoidosis and nephrotic syndrome (NS)1,2 at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 in Orlando, FL October 16-19, 2023.

Key Points: 
  • Patients were monitored at the end of a three-month cycle for a partial or complete response.
  • The full data manuscript from this study was published in ClinicoEconomics and Outcomes Research on October 17, 2023.
  • "We are pleased to have shared our latest health economics research on Acthar Gel.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economics outcomes may not be solely attributable to Acthar.

Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV

Retrieved on: 
Thursday, October 19, 2023
Nexus, Markov, Pharmacy, OBR, Academy of Managed Care Pharmacy, Observation, Fungal infection, HIV, News, Acquisition, Nursing care plan, Journal, QALY, ART, Quality-adjusted life year, Database, Clinical trial, Abstract, HTE, Ibalizumab, Health, ICER, AMCP, SMR, EHR, Bronze medal, Bias, TSX, Health care, Pharmaceutical industry

The analysis, which was presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 conference in Orlando, Fla., suggests that adding ibalizumab to routine clinical care may provide payers with a cost-effective treatment option that can substantially improve outcomes for HTE individuals with HIV.

Key Points: 
  • The analysis, which was presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 conference in Orlando, Fla., suggests that adding ibalizumab to routine clinical care may provide payers with a cost-effective treatment option that can substantially improve outcomes for HTE individuals with HIV.
  • The analysis encompassed numerous costs, including those for treatment acquisition and administration, monitoring, adverse events, opportunistic infections, and terminal care.
  • Mortality assumptions and health-state utility values were based on disease-specific published literature and clinical trial data.
  • Over a lifetime horizon, the addition of ibalizumab to OBR increased the time patients’ HIV remained undetectable (less than 50 copies/ml) or suppressed (between 50 and 200 copies/ml).

Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

Retrieved on: 
Tuesday, October 17, 2023
Nexus, Food, Expo Hall, T2D, Standard of care, QALY, Risk, Hospital, Orlando World Center Marriott, Death, Mortality, AMCP, Academy of Managed Care Pharmacy, HF, FDA, ED, Heart failure, Quality-adjusted life year, National meetings of the Workers' Party of Korea, Cypress, Life imprisonment, Pharmacy, Regulation of tobacco by the U.S. Food and Drug Administration, SOC, Patient, Health insurance, Pharmaceutical industry

THE WOODLANDS, Texas, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today highlighted upcoming presentations of two studies demonstrating positive financial impact of INPEFA® (sotagliflozin) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting, October 16-19, 2023, at the Orlando World Center Marriott, Expo Hall, Cypress 1 and 2, Orlando, Florida.

Key Points: 
  • The budget impact was modeled as the change in medical and pharmacy costs from using sotagliflozin in addition to the standard of care (SoC) compared with the SoC alone among U.S. patients hospitalized with heart failure (HF).
  • Costs included pharmacy, inpatient, emergency department visits, and other medical and adverse event costs.
  • Amongst treated patients on sotagliflozin, commercial payers incurred increased pharmacy costs of $7,276 per patient per year as compared to patients on SoC alone.
  • Clinical outcomes of interest were hospital readmissions, emergency department (ED) visits, and all-cause deaths after an HF hospitalization.

Alliance for Aging Research on First 10 Part D Drugs Subject to Medicare Price-Setting: Today is Not a Reason to Celebrate

Retrieved on: 
Wednesday, August 30, 2023
CMS, COSPAR International Reference Atmosphere, Centers for Medicare & Medicaid Services, Atrial fibrillation, Stroke, Policy, Health equity, Pharmacy, Part, Open enrollment, IRA, Government, National Council on Disability, QALY, Medicare, Martin PBM Mariner, Ageing, MHS, Congressional Budget Office, Alliance for Aging Research, H.R. 3, Disability, Patient, National Council, Economic policy of the Donald Trump administration, CBO, Presidency of Donald Trump, External, Research, Rheumatoid arthritis, Pharmaceutical industry, Health insurance

WASHINGTON, Aug. 29, 2023 /PRNewswire/ -- This morning, the Centers for Medicare and Medicaid Services (CMS) announced the first 10 Part D drugs to be subject to Medicare price-setting .

Key Points: 
  • WASHINGTON, Aug. 29, 2023 /PRNewswire/ -- This morning, the Centers for Medicare and Medicaid Services (CMS) announced the first 10 Part D drugs to be subject to Medicare price-setting .
  • Sue Peschin, MHS, President and CEO at the Alliance for Aging Research, issued the following statement in response:
    The process instead captures drugs that serve large numbers of beneficiaries at modest cost rather than high-cost drugs.
  • "Staging a celebration to announce the first 10 Part D drugs subject to CMS' government price-setting in the Medicare program is macabre and misleading.
  • We have opposed every Medicare price-setting proposal since 2019 because their value frameworks combine analyses of both cost-effectiveness and budget impact.

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

Retrieved on: 
Friday, August 4, 2023
Oncology, Health, Other Health, Research, Science, Pharmaceutical, Biotechnology, HU, Ruxolitinib, Medical Affairs Bureau, Senior, Hydroxycarbamide, Life imprisonment, Ropeginterferon alfa-2b, Case Comprehensive Cancer Center, Quality of life, National Comprehensive Cancer Network, Quality-adjusted life year, Journal of Comparative Effectiveness Research, Polycythemia vera, PV, MS, NCCN, QALY, Journal, Peginterferon alfa-2a, Journal of the National Comprehensive Cancer Network, Polycythemia, Patient, HIV disease progression rates, Risk, Phlebotomy, Treatment, Hematology, Mortality, TES, Myeloproliferative neoplasm, Safety, News, MPN, Pharmaceutical industry, MD

The analysis, titled “Cost-Effectiveness of Ropeginterferon Alfa-2b-njft for the Treatment of Polycythemia Vera,” showed that ropeginterferon alfa-2b-njft provided a cost-effective benefit for a broad range of patients with polycythemia vera (PV) versus first-line hydroxyurea followed by ruxolitinib.

Key Points: 
  • The analysis, titled “Cost-Effectiveness of Ropeginterferon Alfa-2b-njft for the Treatment of Polycythemia Vera,” showed that ropeginterferon alfa-2b-njft provided a cost-effective benefit for a broad range of patients with polycythemia vera (PV) versus first-line hydroxyurea followed by ruxolitinib.
  • Cost effectiveness was demonstrated in a modeled population including both low- and high-risk patients receiving first- or second-line treatment with ropeginterferon alfa-2b-njft.
  • Findings from the study conclude ropeginterferon alfa-2b-njft is a cost-effective treatment option for a broad range of patients with PV, including both low- and high-risk patients and patients with and without prior cytoreductive treatment with hydroxyurea.
  • “Ropeginterferon alfa-2b-njft has demonstrated safety and efficacy in studies including both low- and high-risk patients and patients with and without prior cytoreductive treatment with HU.

Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests

Retrieved on: 
Wednesday, May 3, 2023
Health, Medical Devices, Diabetes, Health Technology, General Health, Clinical Trials, Pharmaceutical, CGM, Hypoglycemia, Blood, Probability, National Health Service, Type 2 diabetes, IQVIA, Life imprisonment, Fear, Quality of life, Hyperglycemia, Multimedia, Research, Quality-adjusted life year, QALY, Risk, DXCM, Patient, NHS, Engineered wood, Pharmaceutical industry, Dexcom, Glycated hemoglobin

The analysis suggests that, compared to finger pricks, use of rtCGM results in significant improvements in baseline glycated haemoglobin (HbA1c), as well as reductions in long-term diabetes-related complications and emergency department visits1.

Key Points: 
  • The analysis suggests that, compared to finger pricks, use of rtCGM results in significant improvements in baseline glycated haemoglobin (HbA1c), as well as reductions in long-term diabetes-related complications and emergency department visits1.
  • The cost-effectiveness of Dexcom rtCGM was sensitive to capture the quality of benefits associated with reduced fear of hypoglycaemia and avoidance of testing with finger pricks, as well as the HbA1c benefit associated with rtCGM use1.
  • Patients using rtCGM were assumed to have a 0.56% reduction in HbA1c based on the mean difference between groups after 12 months of follow-up.
  • Reduced fingerstick testing when using rtCGM was associated with a quality of life (QoL) benefit.

Calliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with IgA Nephropathy in the United States

Retrieved on: 
Tuesday, April 11, 2023
Hypersensitivity, Erythromycin, Kidney disease, Budesonide, Diabetes, Osteoporosis, Fetus, Pregnancy, Cataract, Dialysis, Contraindication, Capsule, Patient, CALT, Risk, Randomized controlled trial, Miscarriage, Ciclosporin, Disease, Outcomes research, Research, HPA, CYP3A4, Measles, Hypertension, Proteinuria, Administration, Anaphylaxis, Ketoconazole, ICER, Death, Indinavir, Itraconazole, Vaccine, EGFR, Parasitism, SOC, Liver, Tropical ulcer, QALY, Adrenal insufficiency, Standard of care, Drug interaction, Immune system, Infection, Glaucoma, Saquinavir, ClinicoEconomics and Outcomes Research, Ritonavir, Birth, Prediabetes, Immunosuppression, UPCR, Pharmaceutical industry, Dietary supplement, IgA nephropathy

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) versus standard of care (SOC) for people with Primary IgA Nephropathy (IgAN) in the United States (US).

Key Points: 
  • NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) versus standard of care (SOC) for people with Primary IgA Nephropathy (IgAN) in the United States (US).
  • Health-state occupancy probabilities and key model inputs were based on the individual patient-level data from NefIgArd, the Phase 3 randomized controlled trial evaluating Nefecon.
  • Andrew Udell, president, North America at Calliditas stated: “These findings are timely and relevant in light of the 2-year eGFR results from the NefIgArd trial we recently announced.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Why focusing on COVID deaths undercounts the health harms of the pandemic – new research

Retrieved on: 
Wednesday, April 12, 2023
Vaccine, Depression, Anxiety, COVID-19, Overalls, Health status of White Americans, Woman, Global health, Research, COVID, Life expectancy, Self-care, Pain, QALY, Quarantine, Death, Pandemic, Population, Social isolation, Ageing, Health, Mental health, Pharmaceutical industry, Quality-adjusted life year

In a new study we’ve attempted to quantify how the COVID pandemic has affected global health using an international survey of the general public.

Key Points: 
  • In a new study we’ve attempted to quantify how the COVID pandemic has affected global health using an international survey of the general public.
  • Health economists often quantify health using a metric known as the quality-adjusted life year (QALY).
  • The idea is to assign a value to each year of a person’s life based on their overall health.
  • To ascertain how people thought the pandemic had affected them, we asked them to rate their current health compared with a year before.

What we found

    • Anxiety and depression was the aspect of health that worsened the most, especially for younger people (aged under 35) and women.
    • Translating the health reductions into a QALY measure indicated that during the pandemic perceived health was around 8% lower on average.
    • Similarly, some countries offered economic support to those in financial difficulties, which may have positively impacted their mental wellbeing.
    • QALYs provide a way of quantifying the trade-offs that exist between the positive and negative effects of different strategies.

Lessons for future pandemics

    • Measuring multiple aspects of health through QALYs would also be a useful supplement to existing measures focusing on cases and deaths.
    • Moving beyond counting deaths to understanding the overall health of the population globally can help us to be better prepared for potential future health shocks.
    • The view expressed are those of the author and not necessarily those of the EuroQol Research Foundation.